Jasper Therapeutics Inc (JSPR)
Jasper Therapeutics Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker JSPR. The company is developing therapies for mast cell-related conditions and diseases tied to hematopoietic stem cells. Its lead candidate, briquilimab, is a monoclonal antibody intended to interfere with CD117 signaling by preventing stem cell factor from binding to the receptor. Jasper is also working on treatment approaches for chronic spontaneous urticaria, chronic inducible urticaria, asthma, and conditioning use in stem cell transplantation for disorders such as sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. The company was founded in 2018 and is based in Redwood City, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JSPR
|
Not available
|
$20 4,164.4% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
13.7x
|
15.612 M
|
12.289 M
|
1.4%
|
-51.3
|
189.9%
|
